Meniere Disease – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Meniere Disease – Pipeline Review, H2 2016’, provides an overview of the Meniere Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Meniere Disease

The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects

The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Meniere Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Orbis Biosciences Inc

Otonomy, Inc.

Quark Pharmaceuticals, Inc.

Sound Pharmaceuticals, Inc.

Synphora AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Meniere Disease Overview 6

Therapeutics Development 7

Pipeline Products for Meniere Disease - Overview 7

Meniere Disease - Therapeutics under Development by Companies 8

Meniere Disease - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

Meniere Disease - Products under Development by Companies 13

Meniere Disease - Companies Involved in Therapeutics Development 14

Orbis Biosciences Inc 14

Otonomy, Inc. 15

Quark Pharmaceuticals, Inc. 16

Sound Pharmaceuticals, Inc. 17

Synphora AB 18

Meniere Disease - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

betamethasone valerate ER - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

dexamethasone acetate SR - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

latanoprost - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

OR-105 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

QPHL-2 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

SPI-1005 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Meniere Disease - Dormant Projects 38

Meniere Disease - Product Development Milestones 39

Featured News & Press Releases 39

Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients 39

Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease 39

Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss 40

Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease 40

Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting 41

Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease 41

May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease 41

Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients 42

Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease 43

Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study 43

Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease 43

Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference 44

Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In Ménière’s Disease 45

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Meniere Disease, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Comparative Analysis by Unknown Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Meniere Disease – Pipeline by Orbis Biosciences Inc, H2 2016 14

Meniere Disease – Pipeline by Otonomy, Inc., H2 2016 15

Meniere Disease – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 16

Meniere Disease – Pipeline by Sound Pharmaceuticals, Inc., H2 2016 17

Meniere Disease – Pipeline by Synphora AB, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Meniere Disease – Dormant Projects, H2 2016 38

List of Figures

List of Figures

Number of Products under Development for Meniere Disease, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports